Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chirag Bavishi

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Cardiovascular Revascularization Medicine : Including Molecular Interventions|June 28, 2025
Editorial: Concomitant transcatheter edge-to-edge repair of mitral and tricuspid regurgitationChirag Bavishi
Annals of Internal Medicine|April 3, 2023
In older adults with hypertension, chlorthalidone vs. hydrochlorothiazide did not reduce major CV events or deaths at 2.4 yChirag Bavishi
Annals of Internal Medicine|April 6, 2026
BP-lowering drugs reduced major CV events to a similar extent in patients with or without isolated diastolic hypertensionChirag Bavishi,
US Cardiology|November 4, 2024
Transcatheter Left Atrial Appendage Closure: Devices Available, Pitfalls, Advantages, and Future DirectionsChirag Bavishi
Annals of Internal Medicine|October 19, 2020
In ACS treated with drug-eluting stents and 3 mo of DAPT, ticagrelor monotherapy reduced clinical events at 1 y vs. DAPTChirag Bavishi
Annals of Internal Medicine|December 5, 2022
In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 dChirag Bavishi
Annals of Internal Medicine|January 2, 2023
Statins increase muscle pain or weakness at 1 y, with an absolute excess of 11 events/1000 person-yChirag Bavishi
Annals of Internal Medicine|March 4, 2024
In adults with stable angina, PCI vs. a placebo procedure reduced angina symptoms at 12 wkChirag Bavishi
Annals of Internal Medicine|July 3, 2023
In HF with secondary mitral regurgitation, transcatheter mitral valve repair reduced HF hospitalizations at 5 yChirag Bavishi
Annals of Internal Medicine|March 6, 2023
Antihypertensive therapy reduced incident dementia vs. placebo at a median 4.3 yChirag Bavishi
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Cardiovascular Revascularization Medicine : Including Molecular Interventions|June 28, 2025
Editorial: Concomitant transcatheter edge-to-edge repair of mitral and tricuspid regurgitationChirag Bavishi
Annals of Internal Medicine|April 3, 2023
In older adults with hypertension, chlorthalidone vs. hydrochlorothiazide did not reduce major CV events or deaths at 2.4 yChirag Bavishi
Annals of Internal Medicine|April 6, 2026
BP-lowering drugs reduced major CV events to a similar extent in patients with or without isolated diastolic hypertensionChirag Bavishi,
US Cardiology|November 4, 2024
Transcatheter Left Atrial Appendage Closure: Devices Available, Pitfalls, Advantages, and Future DirectionsChirag Bavishi
Annals of Internal Medicine|October 19, 2020
In ACS treated with drug-eluting stents and 3 mo of DAPT, ticagrelor monotherapy reduced clinical events at 1 y vs. DAPTChirag Bavishi
Annals of Internal Medicine|December 5, 2022
In acute decompensated HF, adding acetazolamide to IV loop diuretics reduced congestion at 3 dChirag Bavishi
Annals of Internal Medicine|January 2, 2023
Statins increase muscle pain or weakness at 1 y, with an absolute excess of 11 events/1000 person-yChirag Bavishi
Annals of Internal Medicine|March 4, 2024
In adults with stable angina, PCI vs. a placebo procedure reduced angina symptoms at 12 wkChirag Bavishi
Annals of Internal Medicine|July 3, 2023
In HF with secondary mitral regurgitation, transcatheter mitral valve repair reduced HF hospitalizations at 5 yChirag Bavishi
Annals of Internal Medicine|March 6, 2023
Antihypertensive therapy reduced incident dementia vs. placebo at a median 4.3 yChirag Bavishi
Pageof 11